Up to 42% of patients thought to be in low or moderate disease activity were found to be in high disease activity when measured by Vectra and at risk for joint damage. Vectra helps identify risk so action can be taken earlier.
Evaluate the success of controlling inflammation by using Vectra and monitoring the scores over time.
An evaluation that combines the molecular measures of biomarkers with the patient and rheumatologist assessments provides the most comprehensive approach to inform treatment decisions.
Vectra now accounts for age, gender and adiposity for a more personalized score.
Vectra is the best predictor of future joint damage. The Adjusted Vectra Score was validated in four cohorts combined as a superior prognostic of radiographic progression, compared with conventional measures.
Vectra can inform the success of treatment when scores are tracked over time. A change in 8 or more units in subsequent Vectra scores reflects a meaningful change and may be considered a tool, combined with a clinical assessment, to optimize treatment decision-making.
Evaluate the success of controlling RA inflammation by using Vectra at initiation of treatment, change in drug treatment or to monitor response to therapy.
Download the brochure to learn more about Vectra and how it can help to improve patient and provider decisions.
The Vectra Report gives a molecular assessment of RA disease. Vectra demonstrates its unsurpassed ability to predict radiographic progression as a personalized inflammatory measure for patients with RA. Vectra is a validated, advanced blood test performed by a CLIA-certified laboratory.
Rheumatology Services Hotline: 800-338-1918
Vectra® Customer Service: 877-743-8639
